Patient and provider barriers to effective management of gout in general practice: a qualitative study

University of Nottingham, Department of Academic Rheumatology, Academic Rheumatology Clinical Sciences Building City Hospital, Nottingham NG5 1PB, UK.
Annals of the rheumatic diseases (Impact Factor: 9.27). 03/2012; 71(9):1490-5. DOI: 10.1136/annrheumdis-2011-200801
Source: PubMed

ABSTRACT To explore patient and provider illness perceptions and barriers to effective management of gout in general practice.
A qualitative study involving semistructured face-to-face interviews with patients and health professionals from 25 Nottinghamshire general practices and one central National Health Service hospital.
Twenty gout sufferers and 18 health professionals (six general practitioners, five hospital physicians, seven practice nurses).
A number of key themes emerged suggesting that several factors impact on patients' access to recommended treatments. The main barriers were patient experiences and lay beliefs of their condition which affected seeking advice and adherence to treatment. There was universal lack of knowledge and understanding of the causes and consequences of gout and that it can be treated effectively by lifestyle change and use of urate lowering therapy (ULT). All participants associated gout with negative stereotypical images portrayed in Victorian cartoons. Many viewed it as self-inflicted or part of ageing and only focused on managing acute attacks rather than treating the underlying cause. The main provider barriers that emerged related to health professionals' lack of knowledge of gout and management guidelines, reflected in the suboptimal information they gave patients and their reluctance to offer ULT as a 'curative' long-term management strategy.
There are widespread misconceptions and lack of knowledge among both patients and health professionals concerning the nature of gout and its recommended management, which leads to suboptimal care of the most common inflammatory joint disease and the only one for which we have 'curative' treatment.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionGout is the most common inflammatory arthritis worldwide and is the only chronic arthritis that potentially can be `cured¿. However, data exploring gout incidence, prevalence and management, assessed at multiple time points in the same population, are sparse, particularly in Asian populations. This study aimed to describe trends in the epidemiology of gout in the general population of Taiwan.Methods The National Health Insurance Research Database was used to identify gout patients and to estimate the prevalence and incidence of gout for each year from 2005 to 2010. The pattern of gout management was also examined.ResultsOf 23,371,362 beneficiaries in 2010 there were 1,458,569 prevalent and 56,595 incident cases of gout, giving a prevalence of 6.24% (95% CI, 6.23% to 6.25%) and an incidence of 2.74 (95% CI, 2.72 to 2.76) per 1,000 person-years. The annual percentage change (APC) of the standardised prevalence was -0.7 (95% CI, -1.7 to 0.3; P¿=¿0.14), suggesting that the prevalence of gout was essentially the same throughout the study. However, The APC of incidence was -13.4 (95% CI, -16.1 to -10.6) between 2005 and 2007 and -2.1 (95% CI, -10.4 to 7.1) between 2007 and 2010. Regions with the highest prevalence and incidence were eastern coast counties and offshore islets, where indigenous people cluster. Among prevalent gout patients in 2010, only 22.93% (95% CI, 22.87% to 23.00%) were prescribed urate-lowering treatment (ULT), which remained unchanged between 2005 and 2010 with an APC of 0.0 (95% CI, -3.8 to 4.0). Uricosuric agents were more commonly prescribed than xanthine oxidase inhibitors in Taiwan.Conclusions In Taiwan 1 in 16 people have gout. While the incidence has decreased recently, the prevalence remains unchanged. Management of gout in Taiwan is poor, with only 1 in 5 affected people being treated with ULT.
    Arthritis Research & Therapy 01/2015; 17(1):13. DOI:10.1186/s13075-015-0522-8 · 4.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify modifiable patient and provider factors associated with allopurinol adherence and the achievement of a serum urate acid (SUA) goal in gout. We identified a retrospective cohort of patients with gout, newly treated with allopurinol. All patient data came from administrative datasets at a large integrated health delivery system. Patients were ≥ 18 years old at time of initial allopurinol dispensing, and had 12 months or more of membership and drug eligibility prior to the index date. Allopurinol adherence was defined as a proportion of days covered ≥ 0.80, evaluated during the first 12 months of observation after the initial dispensing. Multivariable logistic regression was used to examine factors associated with allopurinol nonadherence and attaining an SUA concentration < 6.0 mg/dl. We identified 13,341 patients with gout with incident allopurinol use (mean age 60 yrs, 78% men). Of these, 9581 patients (72%) had SUA measured both at baseline and during followup. Only 3078 patients (32%) attained an SUA target of < 6.0 mg/dl during followup. Potentially modifiable factors associated with treatment adherence and obtaining the SUA goal in the multivariable analysis included concomitant diuretic use, prescriber specialty, and allopurinol dosing practices. Adherent patients were 2.5-fold more likely than nonadherent patients to achieve an SUA < 6.0 mg/dl during observation. Among patients with gout initiating allopurinol in our study, 68% did not reach the SUA goal and 57% of patients were nonadherent. Modifiable factors, including allopurinol dose escalation, treatment adherence, rheumatology referral, and concomitant medication use, could be important factors to consider in efforts aimed at optimizing gout treatment outcomes.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to explore the health literacy of patients dealing with gout and to understand perceptions that might account for non-adherence to urate-lowering therapy (ULT). Semi-structured interviews involving patients with gout were conducted. The transcripts of the interviews were scored by two readers and a coding system to categorize the data was developed. Fifteen patients (14 men, mean age 63 years, mean disease duration 11 years) were interviewed; ten patients were recruited from secondary care and five from primary care. Six patients had gout tophi and 12 patients used ULT. Less than half of the patients were sufficiently aware of the pathophysiological processes that cause gout. Twelve patients indicated that treatment of gout only encompasses treatment of the acute attack. Patients were unaware of long-term treatment goals. Six patients admitted medication non-adherence at some point in time. Several reasons for non-adherence, such as healthcare professionals providing conflicting messages about medication, can be considered preventable. Half of the patients expressed that they, especially at the time of diagnosis, wanted to know more about the cause of gout, treatment goals and long-term consequences. In conclusion, the health literacy of patients dealing with gout was low in our study, especially with regard to medication. Yet, patients often recognized these knowledge gaps. Our data suggest that improving knowledge and addressing common misperceptions in training programmes, may ultimately contribute to adherence to ULT and an optimized outcome in patients with gout. This hypothesis needs to be confirmed in future research.
    Clinical Rheumatology 12/2014; DOI:10.1007/s10067-014-2838-1 · 1.77 Impact Factor


Available from